Article

Abrogating TGFβ signaling in TCR-engineered T cells and enhancing antigen processing by tumor cells promotes sustained therapeutic activity in pancreatic ductal adenocarcinoma

2025-06-08

Abstract excerpt

<h4>ABSTRACT</h4> Pancreatic ductal adenocarcinoma (PDA) is a deadly malignancy with limited effective therapies. Adoptive cell therapy (ACT) is a promising treatment modality for patients with solid tumors but has been limited by the highly fibroinflammatory and immunosuppressive tumor microenvironment (TME). Transforming growth factor-β (TGFβ) participates in the inordinately suppressive TME in PDA. Here, we te...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: 95f6c301-b08c-5168-89cc-e75b61f04a81
DOI: 10.1101/2025.06.04.657887

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Abrogating TGFβ signaling in TCR-engineered T cells and enhancing antigen processing by tumor cells promotes sustained therapeutic activity in pancreatic ductal adenocarcinomaDOI 10.1101/2025.06.04.657887Read

CA19-9 induces microenvironment remodeling in pancreatic ductal adenocarcinomaSemantic proximity Read

Advancing Immunotherapy in Pancreatic Cancer: A Brief Review of Emerging Adoptive Cell TherapiesSemantic proximity Read

Clinically relevant orthotopic pancreatic cancer models for adoptive T cell therapySemantic proximity Read

Targeting tumor-intrinsic TAK1 triggers anti-tumor immunity and sensitizes pancreatic cancer to checkpoint blockadeSemantic proximity Read

Antigen-presenting cancer-associated fibroblasts in murine pancreatic tumors differentially regulate T-cell phenotype and function.Semantic proximity Read

Combined MEK and STAT3 inhibition reprograms stromal inflammation to overcome immunotherapy resistance in pancreatic cancerSemantic proximity Read

The reciprocal regulation between host tissue and immune cells in pancreatic ductal adenocarcinoma: new insights and therapeutic implicationsSemantic proximity Read

Combined KRAS Inhibition and Immune Therapy Generates Durable Complete Responses in an Autochthonous PDAC ModelSemantic proximity Read

Tumor-specific CD4 T cells cooperate with myeloid cells to remodel the pancreatic tumor microenvironment and enable effective immunotherapySemantic proximity Read

Current advances in immunotherapy for KRAS-Mutant pancreatic cancer.Semantic proximity Read

Distinct small molecule inhibitors of Kras specifically prime CTLA4 blockade therapy to transcriptionally reprogram Tregs and overcome resistance to suppress pancreas cancerSemantic proximity Read

Lymph node-targeted Nanovaccine Reshapes the Tumor Microenvironment to Suppress PDAC Progression and MetastasisSemantic proximity Read